References
- Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342(13): 921–9
- Cahn P, Raffi F, Saag M, et al. Virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, doubleblind, multicenter clinical trial. (Abstr 606) Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Feb 10–14, 2003, Boston
- Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results. (Abstr 564b) Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Feb 10–14, 2003, Boston
- Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13(6): F35–43
- Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and is verse drug reactions. Ann Intern Med 1999; 131(2): 81–7
- Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286(20): 2568–77
- Sterling TR, Chaisson RE, Bartlett JG, et al. CD4+ lymphocyte level is better than HlV-1 plasma viral load in determining when to initiate HAART. (Abstr 519) Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Feb 4, 2001, Chicago
- Phair JP, Mellors JW, Detels R, et al. Virologie and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002; 16(18): 2455–9
- Dybul M, Fauci AS, Bartlett JG, et al; Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137(5 Pt 2): 381–433
- Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288(2): 222–35 [Erratum, JAMA 2003, 11(1): 32]
- Valdez H, Connick E, Smith KY, et al; AIDS Clinical Trials Group Protocol 375 Team. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16(14): 1859–66
- Landay AL, Bettendorf D, Chan E, et al. Evidence of immune reconstitution in antiretroviral drug—experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses 2002; 18(2): 95–102
- Jacobson MA, Schrier R, McCune JM, et al. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J Infect Dis 2001; 183(9): 1399–404.
- Lilleri D, Piccinini G, Baldanti F, et al. Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ Tcell response. J Clin Virol 2003; 26(1): 95–100
- Jacobson MA. Human immunodeficiency virus-associated immune reconstitution disease. Am J Med 2001; 110(8): 662–3
- DeSimone JA, Pomerants RJ, Babinchak TJ. Inflammatory reactions in HIV-1—infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133(6): 447–54